Given that oncogenic mutations can result in a tumor cell’s dependence on CDK4, and that CDK4 regulates breast cancer tumor cell stemness [109], these studies suggest that the development of CDK4-specific inhibitors may be beneficial in the treatment of cancer types that rely predominantly on CDK4 expression. This evidence concerns the gene CDK4 and neoplasm.